Target discovery in metabolic disease

被引:13
作者
Dohrmann, CE [1 ]
机构
[1] DeveloGen AG, D-37079 Gottingen, Germany
关键词
D O I
10.1016/S1359-6446(04)03223-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The prevalence of metabolic diseases is taking on epidemic proportions and poses a serious threat to human health. Current treatment options have proven insufficient to cope with obesity and diabetes because they rarely restore normal metabolism and thus leave patients exposed to life-threatening complications. Successful management of these diseases depends on novel, improved therapeutic strategies targeting early intervention in disease progression, Discovery of novel metabolic disease targets has been hampered by the complexity of contributing environmental and genetic factors, as well as the need for potent but safe treatments suitable for chronic diseases. Genomic approaches are excellent tools to manage genetic complexity and have been applied successfully to identify candidate target genes that will lead to the development of novel therapies for metabolic diseases.
引用
收藏
页码:785 / 794
页数:10
相关论文
共 76 条
[1]   Medical significance of Caenorhabditis elegans [J].
Aboobaker, AA ;
Blaxter, ML .
ANNALS OF MEDICINE, 2000, 32 (01) :23-30
[2]   Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes [J].
Ahrén, B ;
Simonsson, E ;
Larsson, H ;
Landin-Olsson, M ;
Torgeirsson, H ;
Jansson, PA ;
Sandqvist, M ;
Båvenholm, P ;
Efendic, S ;
Eriksson, JW ;
Dickinson, S ;
Holmes, D .
DIABETES CARE, 2002, 25 (05) :869-875
[3]   Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation [J].
Albrektsen, T ;
Frederiksen, KS ;
Holmes, WE ;
Boel, E ;
Taylor, K ;
Fleckner, J .
DIABETES, 2002, 51 (04) :1042-1051
[4]   Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes [J].
Ashrafi, K ;
Chang, FY ;
Watts, JL ;
Fraser, AG ;
Kamath, RS ;
Ahringer, J ;
Ruvkun, G .
NATURE, 2003, 421 (6920) :268-272
[5]   Differential gene expression between visceral and subcutaneous fat depots [J].
Atzmon, G ;
Yang, XM ;
Muzumdar, R ;
Ma, XH ;
Gabriely, I ;
Barzilai, N .
HORMONE AND METABOLIC RESEARCH, 2002, 34 (11-12) :622-628
[6]   Pharmacotherapy of obesity: Currently marketed and upcoming agents [J].
Bays H. ;
Dujovne C. .
American Journal of Cardiovascular Drugs, 2002, 2 (4) :245-253
[7]   Gene expression profiling in islet biology and diabetes research [J].
Bernal-Mizrachi, E ;
Cras-Méneur, C ;
Ohsugi, M ;
Permutt, MA .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2003, 19 (01) :32-42
[8]   Systematic approaches to mouse mutagenesis [J].
Brown, SDM ;
Balling, R .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2001, 11 (03) :268-273
[9]   Microarray analysis of gene expression during early adipocyte differentiation [J].
Burton, GR ;
Guan, Y ;
Nagarajan, R ;
McGehee, RE .
GENE, 2002, 293 (1-2) :21-31
[10]   Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance [J].
Conarello, SL ;
Li, ZH ;
Ronan, J ;
Roy, RS ;
Zhu, L ;
Jiang, GQ ;
Liu, F ;
Woods, J ;
Zycband, E ;
Moller, DE ;
Thornberry, NA ;
Zhang, BB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (11) :6825-6830